Navana Pharmaceuticals' profit grew in the first quarter of the current financial year thanks to strong sales.

The pharmaceutical company's profit rose 12 percent year-on-year to Tk 13.37 crore in the July-September period of this year.

Its earnings per share (EPS) rose to Tk 1.25 from Tk 1.11 in the same period last year, according to the company's unaudited financial statements.

The drugmaker attributed the EPS growth to increased revenue and improved material utilisation.

The company's net sales jumped 31 percent year-on-year to Tk 213.74 crore.

Its net operating cash flow per share (NOCFPS) also surged to Tk 2 from Tk 1.19, which the company attributed to higher cash collections from customers compared to payments to drugmaking vendors.

Founded in 1992, Navana Pharmaceuticals operates under two divisions: veterinary and human health, as per its website.

The veterinary division produces and markets veterinary medicines and feed supplements for poultry, dairy, and aqua sectors.

Meanwhile, the human health division manufactures a wide range of products, including tablets, capsules, oral liquids, and eye drops.